Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
NCT01147393 · Weill Medical College of Cornell University · PHASE1/PHASE2 · terminated · last registry update 2018-02-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “closed to enrollment due to slow patient accrual” | – | Registry record, Weill Medical College of Cornell University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MS4A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-02-11Phase 3 first posted: Acerta Pharma BV, Acalabrutinib + Venetoclax (NCT03836261)
- 2018-11-13Phase 3 first posted: National Cancer Institute (NCI), Ibrutinib + Obinutuzumab (NCT03737981)
- 2018-10-10Phase 3 first posted: National Cancer Institute (NCI), Ibrutinib + Obinutuzumab (NCT03701282)
- 2018-07-26Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab (NCT03599245)
- 2018-05-14Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab (NCT03523858)
- 2018-03-26Phase 3 first posted: Haukeland University Hospital, Cyclophosphamide and ATG + Alemtuzumab (NCT03477500)
- 2018-03-12Phase 3 first posted: Janssen Research & Development, LLC, Ibrutinib + Venetoclax (NCT03462719)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision